RU 27987 (trimegestone)

Subscribe to Selected New Research on RU 27987

15 relevant articles (1 outcomes, 5 trials/studies) found for this Bio-Agent

Description: ligand for progesterone receptor; RN given refers to (17beta(S)-isomer

Also Known As:

trimegestone; 17-(2-hydroxy-1-oxopropyl)-17-methylestra-4,9-dien-3-one; 21-hydroxypromegestone; RU 27988; RU-27987; RU-27988; trimegestone, (17beta(R))-isomer

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 58

Experts

1.	Spielmann, D: 2 articles (09/2005 - 08/2005)
2.	Thompson, J: 2 articles (12/2001 - 03/2000)
3.	Wahab, M: 2 articles (12/2001 - 03/2000)
4.	Bouchard, P: 1 article (09/2005)
5.	The Trimegestone 301 Study Group: 1 article (09/2005)
6.	De Cicco-Nardone, F: 1 article (09/2005)
7.	Garcea, N: 1 article (09/2005)
8.	Koninckx, P R: 1 article (08/2005)
9.	Whitehead, Malcolm: 1 article (05/2002)
10.	Al-Azzawi, Farook: 1 article (05/2002)

Related Diseases

1.	Postmenopausal Osteoporosis 05/01/2004 - "OBJECTIVE: To determine the efficacy of estrogen + progestogen therapy with 1 mg 17beta-estradiol and 0.125 mg trimegestone in the prevention of postmenopausal osteoporosis" 08/01/2001 - "Trimegestone is a novel norpregnane progestin, which is being developed, in combination with 17 beta-estradiol, for the treatment of menopausal symptoms and prevention of postmenopausal osteoporosis" Get all the results and reference details, order at left...
2.	Hemorrhage 05/01/2002 - "The objectives of this study were to test the effect of changing the dose of trimegestone and the duration of treatment on the pattern of bleeding in these women who then entered a 6 month extension phase where a single dose of trimegestone was given sequentially combined with E(2)" 09/01/1997 - "OBJECTIVE: To study the effects of oral trimegestone on endometrial histology and vaginal bleeding when given in combination with oral 17-beta-oestradiol" 05/01/2002 - "CONCLUSION: The dose of trimegestone, and not the duration of treatment, appears to be the important determinant of the pattern of bleeding in post-menopausal women on this HRT regimen." 05/01/2002 - "Women who previously received trimegestone doses of 0.05 and 0.1 mg experienced a later onset of bleeding, which was lighter and of shorter duration (P < 0.001) during the extension phase as compared with the first 6 months" 05/01/2002 - "RESULTS: Women who had received trimegestone 0.25 mg/day during the first 6 months experienced no change in the bleeding pattern in the 6 month extension" Get all the results and reference details, order at left...
3.	Uterine Hemorrhage (Uterine Bleeding) 03/01/1999 - "In this multicentre dose-ranging study using randomized parallel groups, four doses of trimegestone were used to compare data on the patterns of uterine bleeding, the endometrial histology, and the control of menopausal symptoms in 203 women who completed treatment for 6 months" 03/01/1999 - "Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study." 03/01/2000 - "The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy." Get all the results and reference details, order at left...
4.	Osteoporosis 08/01/2001 - "A model of osteoporosis in the ovariectomized rat has been used to evaluate the effects of 17 beta-estradiol and trimegestone, alone and in combination, on bone and uterus in these animals" 02/01/2001 - "The effects of trimegestone (1 mg/kg/day orally), a novel norpregnane progestin, and 17 beta-estradiol (10 micrograms/kg/day subcutaneously), alone and in combination, on bone mass and turnover were investigated using an experimental model of osteoporosis involving ovariectomized rats" Get all the results and reference details, order at left...
5.	Breast Neoplasms (Breast Cancer) 09/15/1987 - "RU-27987, a synthetic progestin, which was recently developed by Roussel Uclaf, Paris, was tested for its validity as a ligand to determine the progesterone receptor in breast cancer" 12/01/2005 - "We used Affymetrix GeneChip U133A expression arrays to examine the action of P4 and six clinically relevant synthetic progestins (3-ketodesogestrel, drospirenone, levonorgestrel, medroxyprogesterone acetate, norethindrone acetate, and trimegestone) on the progesterone receptor (PR)-positive T47Dco and the PR-negative T47D-Y breast cancer cell lines" Get all the results and reference details, order at left...
11 Diseases and 15 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Estrogens (Estrogen)
2.	norethindrone acetate (Norlutate)
3.	Norethindrone (Norethisterone)
4.	estradiol valerate (Delestrogen)
5.	Estradiol (Estrace)
6.	Progesterone Receptors (Progesterone Receptor)
7.	Progesterone Congeners
8.	Medroxyprogesterone 17-Acetate (Depo-Provera)
9.	Levonorgestrel (Plan B)
10.	Hormones
12 Drugs and Important Bio-Agents and 11 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>